Fig. 4
Analysis of time to first CID event in patients who (a) received treatment with a LABA and / or LAMA and (b) did not receive treatment with a LABA and / or LAMA prior to the study (ITT population). *p < 0.05, **p < 0.01, ***p < 0.001. The risk of a first CID event was analyzed using a Cox-Proportional Hazard model including study, treatment group, and smoking status as covariates. AB, aclidinium bromide; CID, clinically important deterioration; FF, formoterol fumarate; HR, hazard ratio; ITT, intent-to-treat; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist